MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Change in Cash
-$25,367K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
Loss on extinguishment of note p...
Depreciation expense
Prepaid expenses and other asset...
Others
Negative Cash Flow Breakdown
Repayment of note payable and ex...
Proceeds from at the market offe...
Operating lease liability
Others
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-06-30
2026-03-31
2025-09-30
2025-06-30
Net loss
3,670
38,909
-16,370
-36,071
Stock-based compensation expense
419
-4,103
1,233
3,799
Depreciation expense
2,452
-836
402
832
Loss on sale and disposal of property and equipment, net
-159
-
-
-
Non-cash interest expense
176
-966
551
1,010
Non-cash lease expense
89
-361
198
381
Loss on extinguishment of note payable
-3,354
-
0
0
Change in fair value of derivative liability
33
459
25
190
Gain on modification of lease liability
1,142
-
-
-
Prepaid expenses and other assets
-475
-278
-457
574
Deferred revenue
-
-
0
0
Other receivables
-
-
0
0
Accounts payable, accrued expenses and other liabilities
-221
5,476
-1,205
-2,348
Operating lease liability
-2,769
733
-397
-951
Net cash used in operating activities
6,629
38,671
-15,156
-34,112
Purchases of property and equipment
-
-
0
0
Proceeds from sale of property and equipment
416
-
-
-
Proceeds from stock option exercises
-
-
0
0
Net cash provided by investing activities
416
-
0
0
Proceeds from drawdown of term loans
-
-
0
0
Repayment of note payable and extinguishment costs
32,413
-
-
-
Proceeds from at the market offering of common stock, net of issuance costs
-3,621
-
3,274
347
Payment of debt issuance costs
-
-
0
0
Repayment of term loan
-
-
0
0
Proceeds from issuances under employee stock purchase plan
-40
-
0
41
Net cash (used in) provided by financing activities
-36,074
-
3,274
388
Net decrease in cash, cash equivalents and restricted cash and cash equivalents
-25,367
35,009
-11,882
-33,724
Cash, cash equivalents and restricted cash and cash equivalentsbeginning of period
66,609
66,609
112,215
-
Cash, cash equivalents and restricted cash and cash equivalentsend of period
21,987
47,354
66,609
-
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Net loss
$3,670K
(110.17%↑ Y/Y)
Loss on
extinguishment of note payable
-$3,354K
Proceeds from sale of
property and equipment
$416K
Depreciation expense
$2,452K
(194.71%↑ Y/Y)
Prepaid expenses and
other assets
-$475K
(-182.75%↓ Y/Y)
Stock-based compensation
expense
$419K
(-88.97%↓ Y/Y)
Non-cash interest
expense
$176K
(-82.57%↓ Y/Y)
Loss on sale and
disposal of property and...
-$159K
Non-cash lease expense
$89K
(-76.64%↓ Y/Y)
Net cash used in
operating activities
$6,629K
(119.43%↑ Y/Y)
something is missing
$3,662K
Net cash provided by
investing activities
$416K
Canceled cashflow
$4,165K
Net decrease in
cash, cash...
-$25,367K
(24.78%↑ Y/Y)
Canceled cashflow
$10,707K
Operating lease liability
-$2,769K
(-191.17%↓ Y/Y)
Gain on modification
of lease liability
$1,142K
Accounts payable,
accrued expenses and...
-$221K
(90.59%↑ Y/Y)
Change in fair value of
derivative liability
$33K
(-82.63%↓ Y/Y)
Net cash (used in)
provided by financing...
-$36,074K
(-9397.42%↓ Y/Y)
Repayment of note payable
and extinguishment...
$32,413K
Proceeds from at the
market offering of...
-$3,621K
(-1143.52%↓ Y/Y)
Proceeds from issuances
under employee stock...
-$40K
(-197.56%↓ Y/Y)
Buy us a coffee
Werewolf Therapeutics, Inc. (HOWL)
Werewolf Therapeutics, Inc. (HOWL)